China’s Advaccine Biopharmaceuticals Suzhou Co Ltd will manufacture and sell Inovio Pharmaceuticals Inc’s COVID-19 vaccine candidate in the country, the companies said on Monday.
Advaccine will have the exclusive right to Inovio’s vaccine candidate, INO-4800, in China. The vaccine is currently being tested in two mid-to-late stage trials, one in China and the other in the United States.
Inovio will receive an upfront payment of $3 million and an aggregate of $108 million upon the achievement of specified development and sales-based milestones. It will also be entitled to receive sales royalty.
In September, the U.S. Food and Drug Administration put the phase 3 portion of the U.S. trial on hold, as it sought more information, including details on a delivery device used to inject INO-4800 into skin cells.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News, Breaking News and Coronavirus News here
Comments
0 comment